» Articles » PMID: 11587045

Mortality and Causes of Death in the WHO Multinational Study of Vascular Disease in Diabetes

Overview
Journal Diabetologia
Specialty Endocrinology
Date 2001 Oct 6
PMID 11587045
Citations 433
Authors
Affiliations
Soon will be listed here.
Abstract

Aims/hypothesis: We aimed to examine the mortality rates, excess mortality and causes of death in diabetic patients from ten centres throughout the world.

Methods: A mortality follow-up of 4713 WHO Multinational Study of Vascular Disease in Diabetes (WHO MSVDD) participants from ten centres was carried out, causes of death were ascertained and age-adjusted mortality rates were calculated by centre, sex and type of diabetes. Excess mortality, compared with the background population, was assessed in terms of standardised mortality ratios (SMRs) for each of the 10 cohorts.

Results: Cardiovascular disease was the most common underlying cause of death, accounting for 44 % of deaths in Type I (insulin-dependent) diabetes mellitus and 52 % of deaths in Type II (non-insulin-dependent) diabetes mellitus. Renal disease accounted for 21% of deaths in Type I diabetes and 11% in Type II diabetes. For Type I diabetes, all-cause mortality rates were highest in Berlin men and Warsaw women, and lowest in London men and Zagreb women. For Type II diabetes, rates were highest in Warsaw men and Oklahoma women and lowest in Tokyo men and women. Age adjusted mortality rates and SMRs were generally higher in patients with Type I diabetes compared with those with Type II diabetes. Men and women in the Tokyo cohort had a very low excess mortality when compared with the background population.

Conclusion/interpretation: This study confirms the importance of cardiovascular disease as the major cause of death in people with both types of diabetes. The low excess mortality in the Japanese cohort could have implications for the possible reduction of the burden of mortality associated with diabetes in other parts of the world.

Citing Articles

Choroidal thickness as predictor of subclinical carotid atherosclerosis in adults with type 1 diabetes.

Castelblanco E, Salvador-Miras I, Carbonell M, Gratacos M, Traveset A, Correig E Sci Rep. 2025; 15(1):8360.

PMID: 40069268 PMC: 11897364. DOI: 10.1038/s41598-025-93534-z.


A Resampling Approach for Causal Inference on Novel Two-Point Time-Series with Application to Identify Risk Factors for Type-2 Diabetes and Cardiovascular Disease.

Dai X, Mouti S, Vale M, Ray S, Bohn J, Goldberg L Stat Biosci. 2025; 17(1):78-131.

PMID: 40061216 PMC: 11889075. DOI: 10.1007/s12561-023-09390-w.


Association of accelerated phenotypic aging, genetic risk, and lifestyle with progression of type 2 diabetes: a prospective study using multi-state model.

Pan L, Liu Y, Huang C, Huang Y, Lin R, Wei K BMC Med. 2025; 23(1):62.

PMID: 39901253 PMC: 11792689. DOI: 10.1186/s12916-024-03832-y.


Insights into the molecular underpinning of type 2 diabetes complications.

Singh A, Bocher O, Zeggini E Hum Mol Genet. 2025; 34(6):469-480.

PMID: 39807636 PMC: 11891870. DOI: 10.1093/hmg/ddae203.


Application of adipose tissue-derived stem cell therapy with a clinically relevant dose does not significantly affect atherosclerotic plaque characteristics in a streptozotocin-induced hyperglycaemia mouse model.

Korn A, Simsek S, Fiet M, Waas I, Niessen H, Krijnen P J Mol Cell Cardiol Plus. 2025; 9():100083.

PMID: 39803590 PMC: 11708420. DOI: 10.1016/j.jmccpl.2024.100083.